Skip to main content
. 2022 Aug 3;83:104200. doi: 10.1016/j.ebiom.2022.104200

Figure 2.

Figure 2

EGFR 19Del/T790M-cis-L792F was related to the third-generation EGFR TKI resistance. (a-b). Representative cell viability curve (left panel) and osimertinib half-maximal inhibitory concentration (IC50) value (right panel) in the H1975 (a, p=0.02) and PC-9 (b, p=0.027) cells transfected with L792Fcis mutation under osimertinib treatment for 72 h (n = 3). (Statistical differences were evaluated using t test). (c). Growth curves of the control and L792Fcis groups of H1975 (left panel) and PC-9 (right panel) for 24, 48, 72, and 96 h using the MTS assay (n = 3). (d). Tumor images and weights from H1975 (control and L792Fcis, upper panel, p=0.74) and PC-9 (control and L792Fcis, down panel, p=0.48) cells (n = 3). (Statistical differences were evaluated using t test). (e-f). Tumor growth curves (e) and tumor weights (f) in the PC-9 control and PC-9 L792Fcis mice models with control (5% dimethyl sulfoxide, 40% PEG300, 5% Tween 80, and 50% water) or osimertinib (10 mg/kg, 5 days a week) treatments at the indicated time points (n = 5, p=0.027. Statistical differences were evaluated using t test). Scale bar, 1 cm.